Recombinant CD4 (Clenoliximab Biosimilar) antibody

Catalog No. ABIN7795103

This Mouse Monoclonal antibody specifically detects in FACS and in vivo. It exhibits reactivity toward Human.

Quick Overview for Recombinant CD4 (Clenoliximab Biosimilar) antibody (ABIN7795103)

Target: CD4 (Clenoliximab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: Un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details

Expression System: Mammalian cells

Purpose: Clenoliximab Biosimilar, CD4 Monoclonal Antibody

Characteristics: Clenoliximab Biosimilar uses the same protein sequences as the therapeutic antibody clenoliximab. Clenoliximab is a chimeric monoclonal antibody from Macaca irus against CD4 which acts as an immunomodulator. It has investigated for the treatment of rheumatoid arthritis. Clenoliximab is a macaque-human chimeric monoclonal antibody (immunoglobulin G4)that binds specifically to the CD4 receptor present on T-lympocytes (Helper T lymphocytes). CD-4 lymphocytes are implicated in the pathogenesis of rheumatoid arthritis (RA). Clenoliximab coats the CD4 T-lymphocytes and thus down-modulates the CD4 T-lympocytes in a dose and concentration-dependent manner without decreasing the amount of CD4 T-lympocytes in circulation.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human CD4

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details

Target: CD4 (Clenoliximab Biosimilar)

Alternative Name: Clenoliximab Biosimilar

Target Type: Biosimilar